06 March 2012
Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.
Rusnano, as the state-owned company is known, and Domain will invest in about 20 U.S.-based health-care technology companies involved in pharmaceuticals, biotechnology and medical devices, the Moscow-based company said today in an e-mailed statement. The partners plan to bring in co-investors, according to the statement.
Print16 May 2024
NovaMedica team participates in the Russian Pharmaceutical Forum in St. Petersburg
14 May 2024
27 April 2024
Cell therapy could help curb progression of heart failure
20 May 2024
China may find various medicines from the Gamaleya Center interesting
20 May 2024
The number of conducted clinical trials in Russia is growing
17 May 2024
Russian scientists have created the world’s first drug for muscular dystrophy Mioshi
17 May 2024